CytoDyn Inc has named Pharmaceutical Industry Veteran Seenu Srinivasan as Executive Director of CMC Regulatory Affairs

Srinivasan is a former director of CMC Regulatory Affairs for Regeneron Pharmaceuticals and has 30 years of extensive regulatory and drug development experience

CytoDyn Inc announced the appointment of Seenu Srinivasan as the company’s new Executive Director of Chemistry, Manufacturing and Controls (CMC) Regulatory Affairs.

Srinivasan, a former director of CMC Regulatory Affairs for () Inc, brings 30 years of extensive regulatory and drug development experience to his role at CytoDyn, including extensive CMC experience in developing active pharmaceutical ingredients (APIs) and drug products from the early stage to marketing.

“We are very happy, Dr. To add Srinivasan to our CMC regulatory management team, ”said Nader Pourhassan, CEO of CytoDyn, in a statement.

READ: CytoDyn says its final mTNBC report shows a 980% increase in 12-month overall survival with its flagship drug Leronlimab

“His many years of experience and his proven leadership skills will clearly enable him to play a key role in shaping the strategic course for our long-term future,” added Pourhassan.

Srinivasan also commented, “I am thrilled to have the opportunity to join CytoDyn at such an important time as our management team can define and shape the future of the company by advancing our multipathway approach to evaluating Leronlimab for so many potential indications . “

CytoDyn, based in Vancouver, Washington, is a late-stage biotechnology company developing Vyrologix (Leronlimab or PRO 140) to fight multiple diseases. Most importantly, she is working to develop a significant advance in HIV treatment that goes beyond the “AIDS cocktail” pill combination that has kept millions of people alive since the mid-1990s.

Contact Sean at [email protected]